Regulatory Watch
Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Amino Asylum

aminoasylum.com ↗
Founded: 2019 HQ: USA Last reviewed: February 20, 2026
F
Overall Grade
Transparency 15/100
Testing 25/100
Pricing 70/100
Reputation 10/100
Compliance 0/100
Publishes COA No
Third-Party Testing No
FDA Warning Letters 1
Product Types injectable, oral-capsule, research-chemical

Overview

Amino Asylum was one of the largest and most popular grey-market research chemical vendors in the United States, selling peptides, SARMs, nootropics, prohormones, and other compounds at aggressively low prices. In June 2025, the FDA raided Amino Asylum’s warehouse, shutting down operations. The website went offline, payment processing was terminated, and all pending orders were frozen. This represents one of the most significant FDA enforcement actions against a grey-market peptide vendor in 2025.

What Happened

On or around June 18, 2025, federal authorities raided Amino Asylum’s warehouse. Key details:

  • Website immediately went offline — server errors, no communication
  • Multiple community reports on Reddit, Discord, and bodybuilding forums confirmed law enforcement presence at the warehouse
  • All orders frozen, payment pages removed, communication channels dead
  • No official statement from the company
  • Forum reports indicate the FDA had sent multiple warning letters prior to the raid, which Amino Asylum ignored
  • Community rumors suggest products were spiked with undisclosed compounds (one Reddit user reported a “RAD-140” product tested as epistane, a prohormone)
  • Company had been selling compounds in tablet/capsule form at prescription doses, making “research only” claims untenable

Why This Matters

Amino Asylum’s downfall illustrates several critical patterns:

  1. “Research purposes only” is not a legal shield. As established in the All American Peptide case ($3M+ forfeiture) and the Tailor Made Compounding conviction, the FDA’s Intended Use Doctrine looks at marketing, packaging, and dosing — not just disclaimers.

  2. Aggressive pricing often signals cut corners. Amino Asylum undercut competitors significantly. Their Finnrick average score of 5.7 (with scores as low as 2.5) suggests inconsistent quality.

  3. No third-party verification despite claims. Multiple “reviews” praised Amino Asylum’s testing, but objective analysis revealed no publicly accessible third-party COAs.

  4. Payment red flags. The company accepted payment through Venmo — an unusual choice that limits buyer protection and dispute resolution.

Pre-Raid Testing Data

Finnrick Analytics tested 15 samples from Amino Asylum across 8 products before the shutdown:

  • Average score: 5.7/10
  • Minimum score: 2.5/10
  • Maximum score: 8.0/10
  • Last test: March 16, 2025

The wide score range (2.5 to 8.0) indicates severe batch inconsistency.

Current Status

As of February 2026, Amino Asylum’s website remains offline. The FDA raid effectively ended operations.

The Bottom Line

Amino Asylum receives an F grade based on: federal law enforcement raid and shutdown, ignored FDA warning letters, products reportedly spiked with undisclosed compounds, no legitimate third-party testing, payment limited to Venmo, and complete cessation of operations.

This vendor profile is maintained as a historical record and cautionary example.